Pharma BD Deal Intelligence
Novartis paid $5.4 billion for Chiron in 2002 to build a vaccines and blood-testing franchise, but the unit bled money and Novartis unloaded it to GSK for $7.1 billion in 2014—a strategic retreat rather than the platform play it was sold as.
Vaccines play failed: Novartis sold Chiron-derived unit to GSK after operating losses
Full analysis, sources & comparables →Novartis acquired Chiron Corporation for vaccines, blood testing, biopharmaceuticals.
Chiron shareholders approved Novartis' acquisition at $48.00 per share in cash, representing a total value of $5.4 billion and a 32% premium to the unaffected…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis acquired Chiron Corporation for $48 per share ($5.4 billion) in an all-cash transaction, gaining a leading vaccines business, blood testing operations (with Gen-Probe), and a biopharmaceuticals pipeline. Novartis had held a 42% stake in Chiron since 1994.
$15.0B Global Vaccines Market (2006)
The global vaccines market was approximately $15 billion in 2006 with influenza vaccines representing a significant and growing segment. Chiron was the fifth-largest vaccines company globally, producing Fluvirin influenza vaccine and developing meningococcal vaccines. Chiron also had blood testing and biopharmaceutical businesses.
Novartis's $5.4B acquisition of Chiron (it already owned 42%) created Novartis Vaccines and Diagnostics. The deal came after Chiron's Liverpool manufacturing problems disrupted US flu vaccine supply in 2004. Novartis invested heavily in modernizing manufacturing and later sold the vaccines business to GSK in 2014 as part of a major asset swap.
Novartis AG closes acquisition/merger of Chiron Corporation for $5.4B, establishing strategic position and initiating integration.
Novartis acquired Chiron for $5.4B to enter vaccines but the division lost money leading to $7.1B sale to GSK in 2014 as strategic retreat.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Chiron Corporation (this deal) | 2002 | $5.4B | 53 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2002 deals · Novartis AG deals · Infectious Disease deals